Angelos M. Stergiou, President and CEO of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), filed a statement of changes in beneficial ownership on November 20, 2026, reporting a sale of common stock on November 18, 2026, related to the vesting of restricted stock units.
Key Highlights
- Reporting person: Angelos M. Stergiou, serving as both Director and President and CEO of SELLAS Life Sciences Group, Inc.
- Shares disposed: 26,606 shares of common stock were sold on November 18, 2026, at a price of $19.178 per share.
- Remaining holdings: Following the transaction, Stergiou directly beneficially owned 1,734,896 shares of common stock.
- Transaction code: The disposal was coded "S" and classified as a mandated "sell to cover" transaction to satisfy tax withholding obligations.
- RSU trigger: The vesting event was linked to SELLAS meeting the primary endpoint in its Phase 3 REGAL study, according to the filing.
- Non-discretionary nature: The filing states these sales "do not represent discretionary trades by the Reporting Person" and were mandated under the issuer's equity incentive plan.
SELLAS Life Sciences CEO Share Disposal Tied to Phase 3 REGAL Study Milestone
According to the filing, the 26,606 shares of SELLAS Life Sciences Group common stock were sold at $19.178 per share to satisfy Stergiou's tax withholding obligation arising from the performance-based vesting of previously granted restricted stock units. The vesting was triggered by the company meeting the primary endpoint in its Phase 3 REGAL study, a clinical milestone for SELLAS, which is a biopharmaceutical company focused on cancer immunotherapies.
The filing's footnote explains that the sales were "mandated as part of the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction." The transaction was not initiated at Stergiou's individual discretion. The filing was signed by Kostantinos Skordalos acting under a power of attorney on behalf of Stergiou and was dated November 20, 2026. Following the disposal, Stergiou's direct beneficial ownership stood at 1,734,896 shares of common stock, with no derivative securities reported in Table II of the filing.
No indirect ownership positions or derivative security transactions were reported. The filing covers only the single common stock disposal transaction dated November 18, 2026, and no amendments to prior filings were noted.
What Was Disclosed
The filing reported the sale of 26,606 shares of SELLAS Life Sciences Group common stock by President and CEO Angelos M. Stergiou on November 18, 2026, at $19.178 per share, executed as a mandatory "sell to cover" transaction to fund tax withholding on vested restricted stock units, leaving him with 1,734,896 shares directly held.



Please wait processing your request...